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Abstract
As an approach to initiating a structure-function analysis of the vaccinia virus I7L core protein
proteinase, a collection of conditional-lethal mutants in which the mutation had been mapped to
the I7L locus were subjected to genomic sequencing and phenotypic analyses. Mutations in six
vaccinia virus I7L temperature sensitive mutants fall into two groups: changes at three positions at
the N-terminal end between amino acids 29 and 37 and two different substitutions at amino acid
344, near the catalytic domain. Regardless of the position of the mutation, mutants at the non-
permissive temperature failed to cleave core protein precursors and had their development
arrested prior to core condensation. Thus it appears that the two clusters of mutations may affect
two different functional domains required for proteinase activity.
Findings
Vaccinia virus (VV) is the prototypic member of the
orthopoxviruses, a genus of large, double-stranded DNA
viruses which includes the human pathogens variola virus
and monkeypox virus. VV has a complex replication cycle
where, as in many other viruses, proteolysis plays a key
role in the maturation process. The initial step in virion
assembly is envelopment of viroplasm by crescent shaped
membranes to form immature virions (IV). The IVs must
then undergo a series of morphological changes, includ-
ing cleavage of a number of core protein precursors, to
become intracellular mature virions (IMV), the first of sev-
eral different infectious forms.
The product of the VV I7L open reading frame (ORF) has
been shown to be the viral core protein proteinase respon-
sible for cleavage of the major core protein precursors P4a
(A10L), P4b (A3L), and P25K(L4R) [1,2]. It is a cysteine
proteinase, with a catalytic triad consisting of a histidine,
an aspartate and a cysteine residue [2] and cleaves its sub-
strates at conserved AG*X motifs [3-5]. In addition to the
major core protein precursors, I7L has been shown to
cleave the membrane protein A17L [6] and may also be
responsible for the cleavage of other viral proteins con-
taining the AG*X motif such as A12L and G7L whose
cleavage has been documented but not attributed to a par-
ticular proteinase [5,7].
In the absence of functional I7L, virion morphogenesis is
irreversibly arrested after the formation of IV but prior to
the formation of IMV [6,8,9]. Despite the potential impor-
tance of this enzyme, relatively little is known about the
biochemistry of the cleavage reaction or the structural fea-
tures which allow I7L to direct regulated catalysis. Up to
this point, all attempts to produce purified, functional I7L
have failed, thereby limiting progress in this area. An alter-
native approach for studying the I7L protein is an analysis
of the existing collections of temperature-sensitive (ts)
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Virology Journal 2006, 3:64 http://www.virologyj.com/content/3/1/64mutants. Six ts mutants from the Dales and Condit collec-
tions have been identified as I7L mutants using comple-
mentation analysis [[10] and S. Kato, T. Bainbridge, N.
Moussatche, and R. Condit, personal communications].
Using the classification system proposed by Lackner et al.
(with the original Dales designations in parenthesis),
these are: Cts-16, Cts-34. Dts-4 (260), Dts-8 (991), Dts-35
(5804), and Dts-93 (9281). Though both collections were
created by chemical mutagenesis, the Condit mutants
were derived from the commonly used strain Western
Reserve (WR) [11,12], while the Dales mutants were
derived from the strain IHD-W, an IHD-J subtype [13].
Of the six mutants, Cts-16 has been the best studied and
most frequently used, primarily as a means to establish a
viral infection in the absence of functional I7L. Originally
it was classified as having a wild type pattern of protein
synthesis [11], although it was later shown that while the
major core protein precursors are synthesized, they are
not cleaved at the non-permissive temperature [14]. In
Cts-16, I7L has also been shown to be stably produced at
the non-permissive temperature [9] and is probably
included in the core. The core protein precursors also
localize normally at the non-permissive temperature [14].
Dales grouped his mutants into categories based on the
apparent level of development attained as determined by
electron microscopy. He classified Dts-8 as a category L
mutant ("immature particles with nucleoids and defective
membranes with spicules") and Dts-35 as category O
("immature normal particles and mature particles with
aberrant cores") [13]. Using his classification system, Cts-
16 best fits category K ("granular foci and immature parti-
cles with nucleoids but lacking internal dense material")
or category L. Dales did not assign Dts-93 to a category
while Dts-4 was not included in the original publication.
Cts-34 has also not been described other than as an I7L
mutant.
In order to further characterize these ts viruses and to
determine the exact location of the mutation or mutations
within the I7L ORF of each virus, genomic DNA was
extracted from each virus type. The I7L ORF was PCR-
amplified using the primers CB26 and CB90 [15], and the
same primers used to sequence the purified PCR products.
Multiple copies of the sequence of the WR I7L ORF have
been deposited with GenBank [GenBank: AY49736, Gen-
Bank:AY243312, and GenBank:J03399] and were
obtained for this analysis.
Sequencing of the parental strain IHD-W revealed two dif-
ferences as compared to the I7L ORF of WR with arginine
instead of lysine at amino acid (aa) 287 and glutamine
instead of histidine at aa376 (Figure 1). WR is reported to
have either aspartate or asparagine at aa420 while IHD-W
has asparagine. The I7L ORF sequence from IHD-W was
identical to that of Dts-97, a mutant in the E9 ORF [S.
Kato, T. Bainbridge, N. Moussatche, and R. Condit, per-
sonal communications]. When these polymorphisms are
taken into account, all the I7L ts mutants contain a single
amino acid change. Cts-16, as previously reported and
reconfirmed in our stock, has a proline to leucine change
at aa344 [9]. Cts-34 has glycine to glutamate at aa29, Dts-
4 has serine to phenylalanine at aa37, Dts-8 has proline to
serine at aa344, and both Dts-35 and Dts-93 have aspar-
tate to asparagine at aa35. Interestingly, the mutations
seem to form two clusters with Cts-34, Dts-4, Dts-35, and
Dts-93 containing three different mutations in a stretch of
nine amino acids at the N-terminal end and Cts-16 and
Dts-8 representing two different mutations in a single
amino acid located toward the C-terminus and just down-
stream of the catalytic cysteine. The possible significance
of these groupings is discussed below.
Since the mutants were created by chemical mutagenesis,
there is the possibility of second-site mutations that con-
tribute to the observed phenotype. To check for this, we
attempted to rescue the replication of each virus with plas-
Schematic diagram of the I7L open reading frameFigure 1
Schematic diagram of the I7L open reading frame. The amino acid changes found in the temperature sensitive mutants 
are represented above while the parental polymorphisms are given below. Black bars represent the putative catalytic triad.Page 2 of 7
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were transfected with 2 μg of either the empty vector
pRB21 [16] or pI7L [8], infected at a multiplicity of infec-
tion (MOI) of 2, and incubated at the non-permissive
temperature of 41C. pI7L contains the I7L ORF under the
control of its native promoter and has been shown to give
more efficient rescue than I7L under the control of a syn-
thetic early/late promoter [8]. Mock transfected cells were
also infected at an MOI of 2 and incubated at either 41C
or the permissive temperature of 31C. The cells were har-
vest at 24 hours post infection (hpi), resuspended in 100
μl PBS and subjected to three freeze-thaw cycles. These
lysates were titered onto confluent BSC40 cells in a series
of 10-fold dilutions. After 48 hours of incubation at 31C,
plaques were visualized by staining with 0.1% crystal vio-
let.
All the ts mutants were rescued by the plasmid containing
I7L, while transfection with an empty plasmid caused no
increase in viral titer (Figure 2). This indicates that for
each virus the mutation within the I7L ORF is the primary,
if not only, cause of their temperature sensitive pheno-
type. Transfection with pI7L resulted in a 2.9 to 20.7 fold
increase in viral titer over virus alone at the non-permis-
sive temperature, causing the viruses to reach between 1.3
and 19.1% of their permissive temperature titer. Cts-34
showed the weakest rescue with a fold increase in titer
only about half that of the next lowest value. However, as
discussed below, its electron microscopic appearance and
cleavage activity were identical to those of the other
mutants, indicating that even if a second-site mutation
exists, the affected protein acts with or after I7L. The
degree of leakiness was low for all the mutants with the
non-permissive temperature titer being 1.4% or less than
that of the permissive temperature titer. As such, leakiness
is not expected to have significantly affected the experi-
ments.
Since I7L has been implicated as the core protein protein-
ase, it was of interest to see if the mutants were all defec-
tive in core protein precursor cleavage. Cleavage of the
core protein precursors P4a, P4b, and P25K, products of
Rescue of replication by plasmid born I7LFigur  2
Rescue of replication by plasmid born I7L. BSC40 cells were infected/transfected as indicated and incubated at the permis-
sive (31C) or non-permissive (41C) temperature. At 24 hours after infection, the cells were harvested and the viral titer of the 
diluted cell lysate was determined. Fold increase was determined by dividing the titer by the titer of virus alone at 41C. % is the 
percentage of the viral titer at 31C. Bars = +/-1 standard error.Page 3 of 7
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assessed by western blot. BSC40 cells were infected at an
MOI of 5, incubated at the appropriate temperature and
harvested at 24 hpi. 100 μg/ml rifampicin (Boehringer-
Manheim) and 8 mM hydroxyurea (applied one hour
prior to infection) were used where needed. Cell pellets
were resuspended in 50 μl of buffer and subjected to three
freeze/thaw cycles. Aliquots of lysate were boiled with
sample buffer and separated on 4–12% SDS PAGE gradi-
ent gels for P4a and P4b detection and 12% SDS PAGE
gels for P25K detection. Membranes were incubated with
a 1:1000 dilution of the appropriate polyclonal antibody,
followed by a 1:2000 dilution of an anti-rabbit-HRP sec-
ondary antibody (Promega). Bands were visualized using
the Opti-4CN detection system (BioRad). For all mutants,
cleavage of P4a and P4b occurred at the permissive tem-
perature but was absent or strongly reduced at the non-
permissive temperature (Figure 3A). Cleavage of P25K at
the AG*A site to produce 25 K did not occur at the non-
permissive temperature, while a higher molecular weight
band corresponding to the product created by cleavage at
an AG*S site was present [17]. The banding patterns at the
Analysis of core protein precursor processing at the permissive (31C) and non-permissive (41C) temperaturesFigure 3
Analysis of core protein precursor processing at the permissive (31C) and non-permissive (41C) temperatures. 
(A) Infected BSC40 cells were incubated at the indicated temperature and harvested 24 hours after infection. Lysates were ana-
lyzed by Western blot using antisera against the indicated protein. (B) Infected BSC40 cells were labeled with [35S]-methionine 
and [35S]-cysteine for 45 minutes at 8 hours after infection. Cells were harvested after the pulse (P) and or after being chased 
(C) with unlabeled methionine and cysteine until 24 hours after infection. Immunoprecipitated samples were separated on a 4–
12% SDS PAGE gradient gel. Rifampicin (rif) and hydroxyurea (HU) were used at final concentrations of 100 μg/ml and 8 mM 
respectively.Page 4 of 7
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cells treated with rifampicin, a drug known to inhibit
cleavage of core proteins [18]. Core protein precursor
processing in both parental strains proceeded normally at
41C (data not shown).
The absence of cleavage at the non-permissive tempera-
ture was confirmed for P4a using pulse-chase immuno-
precipitation. 100 mm plates of BSC40 cells were infected
with virus at an MOI of 10 and incubated at 31 or 41C, as
appropriate. At 8 hpi, the cells were labeled with 100 μCi
of [35S]-methionine and [35S]-cysteine (EasyTag
EXPRE35S35S; PerkinElmer) in methionine and cysteine
free media. Rifampicin, where needed, was added at 100
μg/ml. After a 45 minute incubation, pulse wells were har-
vested, while chase wells were washed and treated with
media containing a 100 fold excess of unlabeled methio-
nine and cysteine and rifampicin if necessary. These were
harvested at 24 hpi. Cell pellets were resuspended in 600
μl of RIPA buffer and subjected to three freeze/thaw cycles
and sonication. Samples were centrifuged to remove
debris and the lysate was incubated overnight with poly-
clonal antibodies against P4a followed by a second incu-
bation after the addition of Protein A Sepharose beads
(Amersham BioSciences). The washed beads were boiled
in 20 μl of sample buffer and subjected to electrophoresis
on a 4–12% SDS PAGE gel.
In all virus containing pulse samples, a strong band corre-
sponding to P4a was clearly visible (Figure 3B). For IHD-
W and Dts-4 at 31C, a representative example of the
behavior of the ts viruses at the permissive temperature,
the precursor containing band was strongly diminished
after the chase period while a lower molecular weight
band representing the cleaved product 4a appeared. At the
non-permissive temperature, there was limited change in
the intensity of the precursor and little or no cleavage
product appeared. The pattern seen at the non-permissive
temperature was similar to that of IHD-W infected cells
treated with rifampicin.
The overall morphology of all six mutants was examined
using electron microscopy. BSC40 cells were infected at an
MOI of 10 and, after a one hour absorption period, incu-
bated at 31 or 41C. Infected cells were collected at 24 hpi,
fixed, embedded and stained. Dts-4 grown at 31C was
examined as a representative of the ts mutants at the per-
missive temperature and was wild-type in its appearance.
Both mature, brick-shaped particles with characteristic
biconcave cores and spherical IV containing electron
dense viroplasm were seen (Figure 4A–C). At the non-per-
missive temperature, all the ts mutants were similar in
their microscopic appearance (Figure 4D–I). Normal cres-
cent shaped membranes and IV were seen along with large
numbers of defective IV. Many of the particles had asym-
metrical condensation of the viroplasm, with the mem-
brane sometimes collapsing on the empty side. Others
formed dark, electron dense nucleoids. The appearance of
these mutants is similar to what has previously been
reported for Cts-16 [9,14], Dts-8 [13], and I7L condi-
tional-lethals where I7L expression was inhibited by an
operator/repressor system [6,8]. The appearance of Dts-35
differed from that reported by Dales [13], as particles with
defective cores were not seen. However, Ansarah-
Sobrinho and Moss also reported poorly formed cores in
some of their I7L null mutants [6]. It seems then, that a
deficiency in I7L can manifest itself in two different ways,
with the virion morphology described here having been
the most frequently observed.
Since the mutations in the I7L ts mutants fall into two dis-
tinct groups it is tempting to speculate that they might
affect two different functions of I7L. Our results indicate
that this is not the case, at least at the level of the virion
formation, as all mutants were defective in the cleavage of
core protein precursors and had their development
arrested at a similar stage. Yet the possibility remains that
the mutations affect two different elements required for
proteinase function. The mutation in Cts-16 (and now
Dts-8) at aa344 has been suspected, without proof, to
inhibit protein cleavage by disrupting the arrangement of
the catalytic triad due to its proximity to the cysteine resi-
due at aa328. It is possible that the other mutants, with
amino acid changes at the N-terminus of the protein
between residues 29 and 37, may also sufficiently alter the
structure or stability of the catalytic site to prevent prote-
olysis. However, because of their position this seems less
likely. Instead, we suggest that the mutations occur within
a region that constitutes a separate domain of unknown
function that is necessary for I7L proteinase activity.
Unfortunately the existing threading and homology
model of I7L [15] does not include the 130 N-terminal
most amino acids as this region does not fit any known
structural domain.
Nevertheless, the properties of this region suggest several
potential functions. One possibility is that the mutations
disrupt the binding site of an unidentified co-factor(s)
that I7L is believed to require as I7L produced in a cell-free
translation system lacks cleavage activity [19]. The
affected stretch of amino acids lies within a hydrophobic
region [2], a common characteristic of sites of protein-
protein interaction. The mutations also lie within a region
that shows weak homology to the type II DNA topoi-
somerase of Saccharomyces cerevisiae [9], raising the possi-
bility of a nucleic acid binding site. Adenovirus
proteinase, an I7L homolog, requires both a peptide and
a DNA cofactor for full activity [20]. Alternatively, the
mutations may interfere with a potential regulatory cleav-
age as I7L contains two AG*X motifs at its N-terminal endPage 5 of 7
(page number not for citation purposes)
Virology Journal 2006, 3:64 http://www.virologyj.com/content/3/1/64
Page 6 of 7
(page number not for citation purposes)
Electron micrographs of virus infected BSC40 cellsFigu e 4
Electron micrographs of virus infected BSC40 cells. MOI = 10 and cells were harvested and fixed 24 hours after infec-
tion. Dts-4 at the permissive temperature of 31C (A-C). Dts-4 (D), Cts-16 (E), Cts-34 (F), Dts-8 (G), Dts-35 (H) and Dts-93 (I) 
at the non-permissive temperature of 41C. Bars represent 400 nm except in C, D and F (bar = 200 nm). N, nucleus; m, mito-
chondria; IMV, intracellular mature virion; asterisk, immature viral particle; arrow, representative particles with asymmetrical 
viroplasm condensation; arrow head, nucleoids.
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and third at its C-terminal end. One of these AG*X sites is
directly disrupted by the mutation in Cts-34 (AGL to AEL)
It is important to note that until more detailed structural
and biochemical information about I7L is available, any
conclusions about the processes disrupted by the muta-
tions within these ts mutants are tentative. However, their
location provides a starting point in the search for regions
of I7L important to its activity.
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